There are no items in your cart
In September 2017, Equity Trustees announced a new Medical Health Partnership Program, supporting medical research.
As part of this program, Mater Foundation Brisbane and Mater Research were jointly awarded a $946 000 grant to support a range of projects at Mater in the areas of cancer, diabetes and children’s diseases.
Equity Trustees has directed the combined resources of 24 philanthropic trusts into the Partnership Program which will inject more than $3 million over three years to three nominated charities, including Mater Foundation.
We sincerely thank Equity Trustees and their philanthropic trusts for supporting vital medical research at Mater and for its commitment to improving the lives of so many Australians.
We look forward to sharing the exciting research outcomes that will be uncovered over the next few years thanks to Equity Trustees’ investment.
As part of the Mater Foundation grant, the following Mater researchers have been awarded funding:
Equity Trustees Cancer Award recipient—Dr Felicity Davis
Dr Felicity Davis is a National Health and Medical Research Council (NHMRC) Career Development Fellow and Senior Research Fellow at Mater Research. She heads the new Breast Physiology and Cancer Group. Felicity believes that the key to unlocking the mysteries of breast cancer lies in our understanding of normal breast development and the cellular and molecular changes that occur in breast tissue during pregnancy and breastfeeding.
Her research has already uncovered some of the key pathways governing 'life and death' decisions in the breast under normal conditions.
To read more about Felicity click here.
Associate Professor Ingrid Winkler, Stems Cells and Cancer Research Group
Associate Professor Ingrid Winkler is a National Health and Medical Research Council (NHMRC) Fellow, a Senior Research Fellow at Mater Research and leads the Stem Cells and Cancer Research Group at Mater with a team of seven researchers. Ingrid’s research seeks to understand how local microenvironments (niches) in our body regulate stem cell behaviour.
Ingrid’s innovative research has already led to several discoveries, such as a novel strategy to protect haematopoietic (bone marrow) stem cells from chemotherapy or radiation damage.
To read more about Ingrid click here.
Dr Sumaira Hasnain Immunopathology Research Group
Dr Sumaira Hasnain is a National Health and Medical Research Council (NHMRC) Career Development Fellow and Senior Research Fellow at Mater Research, where she heads the Immunopathology Research Group. Sumaira has an interest in chronic inflammatory diseases such as pulmonary fibrosis, inflammatory bowel disease and diabetes, as well as infectious diseases.
She was the first globally to demonstrate that certain immune factors can regulate protein production in secretory cells in infection and chronic inflammatory diseases.
To read more about Sumaira click here.
Dr Katharine Irvine Macrophage Biology Research Group
Dr Katharine Irvine is a Senior Research Fellow and a Career Track Fellow at Mater Research, working in the Macrophage Biology Research Group.
Kate is passionate about understanding how the liver functions, and the key players in the development of chronic liver disease and its complications.
At Mater Research, Kate is developing research projects that investigate the role of macrophages (a type of white blood cell) in chronic liver disease, as well as working on new collaborations in other chronic diseases with clinical teams at Mater hospitals.
To read more about Katharine click here.
Associate Professor Luregn Schlapbach Paediatric Critical Care Research Group
Associate Professor Luregn Schlapbach is a Paediatric Intensivist at Lady Cilento Children's Hospital in Brisbane, and leads the Sepsis, Infection and Inflammation theme as part of the Paediatric Critical Care Research Group at Mater Research. Luregn’s research focuses on inflammation and infections in critically ill neonates and children, including aspects such as epidemiology, sepsis, immunology and the biology underpinning patient outcomes.
Luregn’s research is moved by the need to understand why some children become critically unwell because of infections, in order to develop better approaches to allow early recognition and targeted treatment of severe infections in children.
Dr Cameron Snell Anatomical Pathology—Breast Cancer
Dr Cameron Snell is an Anatomical Pathologist with Mater Pathology and leads the Cancer Pathology Research Group at Mater Research. Cameron believes that the only way to achieve better therapy outcomes for cancer patients is by understanding which patients are more likely to respond to a given therapy, with the potential to improve survival rates.
Cameron’s research therefore aims to match the most effective cancer therapies to individual patients and he is currently focused on developing novel clinical tests that can predict responses to targeted therapies in cancer.
To read more about Cameron click here.
House for Life sold for close to $1m
Smiddy cyclists end ride at Mater
Smiling for Smiddy 1600 km ride for cancer research set to roll out of Townsville
Mater's Fertility Services boosted by $500 000 Golden Casket donation